For the quarter ended September 2025, Revvity (RVTY Quick QuoteRVTY - Free Report) reported revenue of $698.95 million, up 2.2% over the same period last year. EPS came in at $1.18, compared to $1.28 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $699.98 million, representing a surprise of -0.15%. The company delivered an EPS surprise of +3.51%, with the consensus EPS estimate being $1.14.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Revvity performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Organic revenue growth - Total: 1% versus 0.9% estimated by four analysts on average.
• Organic revenue growth - Life Sciences: 0% versus the three-analyst average estimate of 1.1%.
• Organic revenue growth - Diagnostics: 2% versus the three-analyst average estimate of 0.2%.
• Net Sales- Life Sciences: $342.82 million versus $338.39 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +13.9% change.
• Net Sales- Diagnostics: $356.13 million compared to the $361.25 million average estimate based on four analysts. The reported number represents a change of -7.1% year over year.

View all Key Company Metrics for Revvity here>>>

Shares of Revvity have returned +17.6% over the past month versus the Zacks S&P 500 composite's +2.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.